Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global intracranial therapeutic delivery market is poised for unprecedented growth. According to a comprehensive market analysis, the sector, valued at US$ 2.2 billion in 2024, is projected to burgeon at a compound annual growth rate (CAGR) of 9% over the next decade, culminating in a staggering US$ 4 billion by 2031. This surge reflects the increasing demand for innovative treatments in neurology and the rising prevalence of neurological disorders worldwide.

Intracranial Therapeutic Delivery: A Pillar of Regenerative Medicine

Accounting for approximately 6.1% of the global regenerative medicine market in 2021, intracranial therapeutic delivery stands at the forefront of transforming patient care. With a significant emphasis on cell, gene, and enzyme replacement therapies, this sector promises a new dawn in the treatment of a myriad of conditions, offering hope where traditional modalities fall short.

A Decade in Review: Triumphs and Innovations

The period from 2018 to 2023 has witnessed a notable ascent in the popularity and efficacy of intracranial therapeutic delivery methods, especially in the realms of cell and gene therapy. This paradigm shift, underpinned by extensive research and collaboration among biopharmaceutical giants such as Bristol Myers Squibb, Gilead Sciences & Company, and Xcell Biosciences Inc., underscores a transformative approach to disease management and prevention. The pursuit of excellence by these key players, through strategic acquisitions and partnerships, is setting new benchmarks in the industry.

Market Drivers: A Confluence of Innovation and Opportunity

The market's trajectory is notably influenced by the burgeoning pipeline of cell, gene, and enzyme replacement therapies, which account for a substantial portion of the pharmaceutical industry's research focus. With over 750 trials and more than 200 investigational new drug applications anticipated by the U.S. FDA, the sector is on the cusp of delivering groundbreaking treatments to patients across the globe.

Moreover, a tangible shift towards regenerative therapies over conventional drug-based treatments is reshaping the landscape. These advancements, coupled with supportive government policies, especially in emerging economies, herald a new era of healthcare possibilities.

Challenges and Constraints: Navigating Through Uncertainties

Despite the optimistic outlook, the market faces hurdles, primarily due to the high costs associated with these advanced therapies. The financial implications for patients and healthcare systems, along with a lack of comprehensive reimbursement policies, present significant challenges. Addressing these concerns is crucial for ensuring the accessibility and sustainability of intracranial therapeutic delivery methods.

Geographical Insights: Key Markets and Emerging Players

United States: Leading the charge with a 36.4% market share, the U.S. is a hotbed for R&D, bolstered by robust government support and regulatory frameworks.
Germany: With a quarter share of the European market, Germany's robust healthcare expenditure and thriving biopharmaceutical landscape make it a key player in the sector.
United Kingdom: The U.K.'s commitment to regenerative medicine and its significant contribution to the European advanced therapeutic medicinal products (ATMP) sector underscore its pivotal role in the market's growth.
South Korea: Demonstrating rapid progress, South Korea's strategic investments in biopharma and biotech are unlocking new possibilities in intracranial therapeutic delivery.

The Competitive Landscape: Fostering Innovation and Collaboration

The market's future is shaped by strategic collaborations, mergers, and acquisitions among leading firms. Innovations and product launches are critical for maintaining competitive advantage and addressing the evolving needs of patients worldwide. Notable developments, such as ElevateBio's lentiviral vector production platform and the collaboration between Biogen and Ginkgo Bioworks, highlight the industry's commitment to revolutionizing intracranial therapeutic delivery.

Key Companies Profiled

Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics

Segmentation of Intracranial Therapeutic Delivery Industry

Intracranial Therapeutic Delivery Market by Therapy:

Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy

Intracranial Therapeutic Delivery Market by Indication:

Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis

Intracranial Therapeutic Delivery Market by Region:

U.S. Intracranial Therapeutic Delivery Market
Europe Intracranial Therapeutic Delivery Market
Rest of the World (ROW) Intracranial Therapeutic Delivery Market

1. Executive Summary

1.1. Global Intracranial Therapeutic Delivery Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

3.1. Global Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Cell-based Therapy
  - 3.1.1.2. Gene Therapy
  - 3.1.1.3. Enzyme Replacement Therapy
3.2. Global Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Spinal Muscular Atrophy (SMA)
  - 3.2.1.2. Multiple Sclerosis
  - 3.2.1.3. Batten Disease
  - 3.2.1.4. Amyotrophic Lateral Sclerosis
3.3. Global Intracranial Therapeutic Delivery Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

4.1. North America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Cell-based Therapy
  - 4.1.1.2. Gene Therapy
  - 4.1.1.3. Enzyme Replacement Therapy
4.2. North America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Spinal Muscular Atrophy (SMA)
  - 4.2.1.2. Multiple Sclerosis
  - 4.2.1.3. Batten Disease
  - 4.2.1.4. Amyotrophic Lateral Sclerosis
4.3. North America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

5.1. Europe Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Cell-based Therapy
  - 5.1.1.2. Gene Therapy
  - 5.1.1.3. Enzyme Replacement Therapy
5.2. Europe Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Spinal Muscular Atrophy (SMA)
  - 5.2.1.2. Multiple Sclerosis
  - 5.2.1.3. Batten Disease
  - 5.2.1.4. Amyotrophic Lateral Sclerosis
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
  - 5.3.1.8. Italy Intracranial Therapeutic Delivery Market by Indication, Value (US$Bn), 2018 - 2031
  - 5.3.1.9. Turkey Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

6.1. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Cell-based Therapy
  - 6.1.1.2. Gene Therapy
  - 6.1.1.3. Enzyme Replacement Therapy
6.2. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Spinal Muscular Atrophy (SMA)
  - 6.2.1.2. Multiple Sclerosis
  - 6.2.1.3. Batten Disease
  - 6.2.1.4. Amyotrophic Lateral Sclerosis
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
  - 6.3.1.2. China Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

7.1. Latin America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Cell-based Therapy
  - 7.1.1.2. Gene Therapy
  - 7.1.1.3. Enzyme Replacement Therapy
7.2. Latin America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Spinal Muscular Atrophy (SMA)
  - 7.2.1.2. Multiple Sclerosis
  - 7.2.1.3. Batten Disease
  - 7.2.1.4. Amyotrophic Lateral Sclerosis
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

8.1. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Cell-based Therapy
  - 8.1.1.2. Gene Therapy
  - 8.1.1.3. Enzyme Replacement Therapy
8.2. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Spinal Muscular Atrophy (SMA)
  - 8.2.1.2. Multiple Sclerosis
  - 8.2.1.3. Batten Disease
  - 8.2.1.4. Amyotrophic Lateral Sclerosis
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Therapy vs by Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Novartis AG
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. BioMarin
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. CORESTEM Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Alaunos Therapeutics, Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Apic Bio
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Stemedica Cell Technologies, Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Voyager Therapeutics
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Bayer AG
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Abeona Therapeutics
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Spark Therapeutics
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

List of Region/Countries

North America
- U.S.
- Canada

Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe

Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa